Taiwan Biotech and Elixiron Immunotherapeutics: Pharma Boardroom Interview

In this interview with Pharma Boardroom, Elixiron’s CEO, Hung-Kai Chen talked about Elixiron’s approach to develop unique immunotherapies for hard-to-treat cancers and chronic hepatitis B infection. Dr Chen also shared his vision on the strengths of Taiwan for setting up a biotech company. Read the interview here.